TW202102209A - 低劑量三重組合調配物 - Google Patents

低劑量三重組合調配物 Download PDF

Info

Publication number
TW202102209A
TW202102209A TW109110099A TW109110099A TW202102209A TW 202102209 A TW202102209 A TW 202102209A TW 109110099 A TW109110099 A TW 109110099A TW 109110099 A TW109110099 A TW 109110099A TW 202102209 A TW202102209 A TW 202102209A
Authority
TW
Taiwan
Prior art keywords
dose
pharmaceutical composition
inhibitor
metformin
lowest
Prior art date
Application number
TW109110099A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬 麥克馬宏
安東尼 洛德傑斯
Original Assignee
澳大利亞喬治全球健康研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 澳大利亞喬治全球健康研究所 filed Critical 澳大利亞喬治全球健康研究所
Publication of TW202102209A publication Critical patent/TW202102209A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW109110099A 2019-03-25 2020-03-25 低劑量三重組合調配物 TW202102209A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/364,063 2019-03-25
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation

Publications (1)

Publication Number Publication Date
TW202102209A true TW202102209A (zh) 2021-01-16

Family

ID=72606637

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109110099A TW202102209A (zh) 2019-03-25 2020-03-25 低劑量三重組合調配物
TW114106241A TW202545526A (zh) 2019-03-25 2020-03-25 低劑量三重組合調配物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114106241A TW202545526A (zh) 2019-03-25 2020-03-25 低劑量三重組合調配物

Country Status (11)

Country Link
US (5) US11033544B2 (https=)
EP (1) EP3946344A4 (https=)
JP (1) JP7586830B2 (https=)
KR (1) KR20220004027A (https=)
CN (2) CN113924096A (https=)
AU (2) AU2020247542A1 (https=)
BR (1) BR112021018994A2 (https=)
CA (1) CA3134800A1 (https=)
MX (2) MX2021011746A (https=)
TW (2) TW202102209A (https=)
WO (1) WO2020194052A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
KR102853692B1 (ko) * 2021-07-08 2025-09-02 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
EP4415723A4 (en) * 2021-10-12 2025-09-03 Unison Pharmaceuticals Pvt Ltd PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN
TR2023001202A1 (tr) * 2023-02-02 2024-08-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇
KR20260000968A (ko) * 2024-06-26 2026-01-05 주식회사 종근당 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
BRPI1008560B1 (pt) * 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
EP3142661B1 (en) * 2014-05-16 2021-10-06 Astrazeneca AB Method for suppressing glucagon secretion of an sglt2 inhibitor
US20160067217A1 (en) * 2014-09-09 2016-03-10 ARKAY Therapeutics, LLC Metabolic syndrome treatment
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Also Published As

Publication number Publication date
JP7586830B2 (ja) 2024-11-19
US20220226317A1 (en) 2022-07-21
MX2021011746A (es) 2021-10-22
US20200306246A1 (en) 2020-10-01
CN119607213A (zh) 2025-03-14
US20220226315A1 (en) 2022-07-21
US20220226316A1 (en) 2022-07-21
WO2020194052A1 (en) 2020-10-01
KR20220004027A (ko) 2022-01-11
MX2024013504A (es) 2024-12-06
EP3946344A4 (en) 2022-12-28
TW202545526A (zh) 2025-12-01
CA3134800A1 (en) 2020-10-01
AU2020247542A1 (en) 2021-11-11
EP3946344A1 (en) 2022-02-09
US11033544B2 (en) 2021-06-15
BR112021018994A2 (pt) 2022-02-08
JP2022529208A (ja) 2022-06-20
US20210260056A1 (en) 2021-08-26
CN113924096A (zh) 2022-01-11
AU2025226705A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
TW202102209A (zh) 低劑量三重組合調配物
TW202102208A (zh) 低劑量三重組合調配物
EP1743655B1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CN103458919A (zh) 在2型糖尿病患者中预防低血糖症
CN104349790A (zh) 用于治疗糖尿病的葡萄糖激酶活化剂组合物
EA015382B1 (ru) Применение рофлумиласта для лечения сахарного диабета типа 2
KR20150046125A (ko) Sglt2 저해약과 항고혈압약의 조합
CN111918655A (zh) 治疗患有慢性肾脏疾病的糖尿病受试者的方法
WO2004002473A1 (ja) 血糖コントロール用医薬組成物
TW202408522A (zh) 一種稠環嘧啶類化合物的用途
HK40124034A (zh) 低剂量三联组合制剂
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
HK40067219A (zh) 低剂量三联组合制剂
HK40067275A (zh) 低剂量三联组合制剂
EP4008325A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19
US20230141355A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19
JP2008525314A (ja) 胃不全麻痺様症状の治療及び／又は予防剤
JPWO2002028398A1 (ja) 糖尿病治療用組成物
HK1102405B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
CN1741798A (zh) 预防或治疗子宫内生长迟缓和妊娠毒血症的药物
MX2009012310A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a metformina.